Amended Statement of Ownership (sc 13g/a)
February 13 2020 - 4:08PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
Under the Securities Exchange Act of 1934
(Amendment No. 1)
ALLOGENE
THERAPEUTICS, INC.
(Name of Issuer)
Common Stock
(Title of
Class of Securities)
019770 10 6
(CUSIP Number)
December
31, 2019
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
☐ Rule 13d-1(b)
☐
Rule 13d-1(c)
☒ Rule 13d-1(d)
|
*
|
The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form
with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
|
The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities
Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
|
|
|
|
|
|
|
CUSIP No. 019770 10 6
|
|
13G
|
|
Page
2
of 10 Pages
|
|
|
|
|
|
|
|
|
|
1
|
|
Names of
Reporting Persons
Arie Belldegrun, M.D.
|
|
2
|
|
Check the Appropriate Box if a Member
of a Group
(a) ☐ (b) ☐
|
|
3
|
|
SEC Use Only
|
|
4
|
|
Citizenship or Place of
Organization
United States of America and Israel
|
|
Number of
Shares
Beneficially
Owned by
Each
Reporting
Person
With:
|
|
5
|
|
Sole Voting Power
35,000 Shares
|
|
|
6
|
|
Shared Voting Power
7,319,000 Shares (1)
|
|
|
7
|
|
Sole Dispositive Power
35,000 Shares
|
|
|
8
|
|
Shared Dispositive Power
7,319,000 Shares (1)
|
|
9
|
|
Aggregate Amount Beneficially Owned by Each Reporting Person
7,354,000 Shares
|
|
10
|
|
Check if the Aggregate Amount in Row
(9) Excludes Certain Shares ☐
|
|
11
|
|
Percent of Class Represented by Amount
in Row (9)
6.0% (2)
|
|
12
|
|
Type of Reporting Person
IN
|
|
(1)
|
Includes (a) 719,343 shares of common stock beneficially owned by Bellco Capital, LLC, of which
Dr. Belldegrun is a manager, (b) 3,710,006 shares of common stock beneficially owned by Arie & Rebecka Belldegrun, as Trustees of the Belldegrun Family Trust, (c) 1,197,870 shares of common stock beneficially owned by VVAG Special
Fund LLC (VVAG), of which VVAG LLC is the manager, of which Dr. Belldegrun serves as a senior managing director and (d) 1,691,781 shares of common stock beneficially owned by Vida Ventures LLC (Vida), of which VV Manager LLC is the
manager, of which Dr. Belldegrun is a Senior Managing Director. Dr. Belldegrun disclaims beneficial ownership of the shares held VVAG and Vida, except to the extent of any pecuniary interest therein.
|
|
(2)
|
This percentage is calculated based on 121,902,101 shares of common stock outstanding as of November 1,
2019, as reported in the Issuer’s Quarterly Report on Form 10-Q filed on November 5, 2019.
|
|
|
|
|
|
|
|
CUSIP No. 019770 10 6
|
|
13G
|
|
Page
3
of 10 Pages
|
|
|
|
|
|
|
|
|
|
1
|
|
Names of
Reporting Persons
Arie & Rebecka Belldegrun, as Trustees of the Belldegrun
Family Trust
|
|
2
|
|
Check the Appropriate Box if a Member
of a Group
(a) ☐ (b) ☐
|
|
3
|
|
SEC Use Only
|
|
4
|
|
Citizenship or Place of
Organization
California
|
|
Number of
Shares
Beneficially
Owned by
Each
Reporting
Person
With:
|
|
5
|
|
Sole Voting Power
0 Shares
|
|
|
6
|
|
Shared Voting Power
3,710,006 Shares
|
|
|
7
|
|
Sole Dispositive Power
0 Shares
|
|
|
8
|
|
Shared Dispositive Power
3,710,006 Shares
|
|
9
|
|
Aggregate Amount Beneficially Owned by Each Reporting Person
3,710,006 Shares
|
|
10
|
|
Check if the Aggregate Amount in Row
(9) Excludes Certain Shares ☐
|
|
11
|
|
Percent of Class Represented by Amount
in Row (9)
3.0% (1)
|
|
12
|
|
Type of Reporting Person
OO
|
|
(1)
|
This percentage is calculated based on 121,902,101 shares of common stock outstanding as of November 1,
2019, as reported in the Issuer’s Quarterly Report on Form 10-Q filed on November 5, 2019.
|
|
|
|
|
|
|
|
CUSIP No. 019770 10 6
|
|
13G
|
|
Page
4
of 10 Pages
|
|
|
|
|
|
|
|
|
|
1
|
|
Names of
Reporting Persons
Bellco Capital, LLC
|
|
2
|
|
Check the Appropriate Box if a Member
of a Group
(a) ☐ (b) ☐
|
|
3
|
|
SEC Use Only
|
|
4
|
|
Citizenship or Place of
Organization
Delaware
|
|
Number of
Shares
Beneficially
Owned by
Each
Reporting
Person
With:
|
|
5
|
|
Sole Voting Power
719,343 Shares
|
|
|
6
|
|
Shared Voting Power
0 Shares
|
|
|
7
|
|
Sole Dispositive Power
719,343 Shares
|
|
|
8
|
|
Shared Dispositive Power
0 Shares
|
|
9
|
|
Aggregate Amount Beneficially Owned by Each Reporting Person
719,343 Shares
|
|
10
|
|
Check if the Aggregate Amount in Row
(9) Excludes Certain Shares ☐
|
|
11
|
|
Percent of Class Represented by Amount
in Row (9)
0.6% (1)
|
|
12
|
|
Type of Reporting Person
OO
|
|
(1)
|
This percentage is calculated based on 121,902,101 shares of common stock outstanding as of November 1,
2019, as reported in the Issuer’s Quarterly Report on Form 10-Q filed on November 5, 2019.
|
|
|
|
|
|
|
|
CUSIP No. 019770 10 6
|
|
13G
|
|
Page
5
of 10 Pages
|
|
|
|
|
|
|
|
|
|
1
|
|
Names of
Reporting Persons
VVAG Special Fund LLC
|
|
2
|
|
Check the Appropriate Box if a Member
of a Group
(a) ☐ (b) ☐
|
|
3
|
|
SEC Use Only
|
|
4
|
|
Citizenship or Place of
Organization
Delaware
|
|
Number of
Shares
Beneficially
Owned by
Each
Reporting
Person
With:
|
|
5
|
|
Sole Voting Power
0 Shares
|
|
|
6
|
|
Shared Voting Power
1,197,870 Shares
|
|
|
7
|
|
Sole Dispositive Power
0 Shares
|
|
|
8
|
|
Shared Dispositive Power
1,197,870 Shares
|
|
9
|
|
Aggregate Amount Beneficially Owned by Each Reporting Person
1,197,870 Shares
|
|
10
|
|
Check if the Aggregate Amount in Row
(9) Excludes Certain Shares ☐
|
|
11
|
|
Percent of Class Represented by Amount
in Row (9)
1.0% (1)
|
|
12
|
|
Type of Reporting Person
OO
|
|
(1)
|
This percentage is calculated based on 121,902,101 shares of common stock outstanding as of November 1,
2019, as reported in the Issuer’s Quarterly Report on Form 10-Q filed on November 5, 2019.
|
|
|
|
|
|
|
|
CUSIP No. 019770 10 6
|
|
13G
|
|
Page
6
of 10 Pages
|
|
|
|
|
|
|
|
|
|
1
|
|
Names of
Reporting Persons
Vida Ventures LLC
|
|
2
|
|
Check the Appropriate Box if a Member
of a Group
(a) ☐ (b) ☐
|
|
3
|
|
SEC Use Only
|
|
4
|
|
Citizenship or Place of
Organization
Nevada
|
|
Number of
Shares
Beneficially
Owned by
Each
Reporting
Person
With:
|
|
5
|
|
Sole Voting Power
0 Shares
|
|
|
6
|
|
Shared Voting Power
1,691,781 Shares
|
|
|
7
|
|
Sole Dispositive Power
0 Shares
|
|
|
8
|
|
Shared Dispositive Power
1,691,781 Shares
|
|
9
|
|
Aggregate Amount Beneficially Owned by Each Reporting Person
1,691,781 Shares
|
|
10
|
|
Check if the Aggregate Amount in Row
(9) Excludes Certain Shares ☐
|
|
11
|
|
Percent of Class Represented by Amount
in Row (9)
1.4% (1)
|
|
12
|
|
Type of Reporting Person
OO
|
|
(1)
|
This percentage is calculated based on 121,902,101 shares of common stock outstanding as of November 1,
2019, as reported in the Issuer’s Quarterly Report on Form 10-Q filed on November 5, 2019.
|
|
|
|
|
|
|
|
CUSIP No. 019770 10 6
|
|
13G
|
|
Page
7
of 10 Pages
|
|
|
|
|
|
Item 1(a).
|
|
Name of Issuer:
Allogene Therapeutics, Inc.
|
|
|
|
|
Item 1(b).
|
|
Address of Issuer’s Principal Executive Offices:
210 East Grand Avenue
South San Francisco, CA 94080
|
|
|
|
|
Item 2(a).
|
|
Names of Persons Filing:
Arie Belldegrun, M.D.
Arie & Rebecka Belldegrun, as
Trustees of the Belldegrun Family Trust (the “Belldegrun Trust”)
Bellco Capital LLC
VVAG Special Fund LLC
Vida Ventures LLC
|
|
|
|
|
Item 2(b).
|
|
Address of Principal Business Office, or, if none, Residence:
The address of Arie Belldegrun, M.D. and the Belldegrun Trust is:
811 Strada Vecchia Road, Los Angeles, CA 90077
The address of Bellco Capital LLC is:
2049 Century Park East,
Suite 1940, Los Angeles, CA 90067
The address of VVAG Special Fund LLC and Vida
Ventures LLC is:
40 Broad Street, #201, Boston, MA 02109
|
|
|
|
|
Item 2(c).
|
|
Citizenship:
Arie Belldegrun: USA and Israel
Belldegrun Trust: California
Bellco Capital LLC: Delaware
VVAG Special Fund LLC: Delaware
Vida Ventures LLC: Nevada
|
|
|
|
|
Item 2(d).
|
|
Title of Class of Securities:
Common Stock
|
|
|
|
|
Item 2(e).
|
|
CUSIP No.:
019770 10 6
|
|
|
|
|
Item 3.
|
|
Not Applicable.
|
|
|
|
|
|
|
|
CUSIP No. 019770 10 6
|
|
13G
|
|
Page
8
of 10 Pages
|
The information requested hereinafter is set forth in items 5 through 9 and 11 of the cover page to this Schedule 13G. Ownership is stated as of
December 31, 2019. The ownership percentage is based on 121,902,101 shares of common stock outstanding as of November 1, 2019, as reported in the Issuer’s quarterly report on Form 10-Q filed
November 5, 2019.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Reporting Person
|
|
Shares Held
Directly
|
|
|
Sole
Voting
Power
|
|
|
Shared
Voting
Power
|
|
|
Sole
Dispositive
Power
|
|
|
Shared
Dispositive
Power
|
|
|
Beneficial
Ownership
|
|
|
Percentage
of Class(1)
|
|
|
Arie Belldegrun
|
|
|
35,000
|
|
|
|
35,000
|
|
|
|
7,319,000
|
|
|
|
35,000
|
|
|
|
7,319,000
|
|
|
|
7,354,000
|
|
|
|
6.0
|
%
|
|
|
|
|
|
|
|
|
|
|
Arie and Rebecka Belldegrun, as Trustees of the Belldegrun Family Trust
|
|
|
3,710,006
|
|
|
|
0
|
|
|
|
3,710,006
|
|
|
|
0
|
|
|
|
3,710,006
|
|
|
|
3,710,006
|
|
|
|
3.0
|
%
|
|
|
|
|
|
|
|
|
|
|
Bellco Capital, LLC
|
|
|
719,343
|
|
|
|
0
|
|
|
|
719,343
|
|
|
|
0
|
|
|
|
719,343
|
|
|
|
719,343
|
|
|
|
0.6
|
%
|
|
|
|
|
|
|
|
|
|
|
VVAG Special Fund LLC
|
|
|
1,197,870
|
|
|
|
0
|
|
|
|
1,197,870
|
|
|
|
0
|
|
|
|
1,197,870
|
|
|
|
1,197,870
|
|
|
|
1.0
|
%
|
|
|
|
|
|
|
|
|
|
|
Vida Ventures LLC
|
|
|
1,691,781
|
|
|
|
0
|
|
|
|
1,691,781
|
|
|
|
0
|
|
|
|
1,691,781
|
|
|
|
1,497,336
|
|
|
|
1.4
|
%
|
|
(1)
|
This percentage is calculated based on 121,902,101 shares of common stock outstanding as of November 1,
2019, as reported in the Issuer’s Quarterly Report on Form 10-Q filed on November 5, 2019.
|
|
|
|
|
|
Item 5.
|
|
Ownership of Five Percent or Less of a Class.
|
|
|
|
If this statement is being filed to report the fact that as of the date hereof, the Reporting Persons have ceased to be the
beneficial owner of more than five percent of the class of securities, check the following: ☐
|
|
|
|
|
Item 6.
|
|
Ownership of More than Five Percent on Behalf of Another Person
|
|
|
|
Not applicable
|
|
|
|
|
Item 7.
|
|
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person
|
|
|
|
Not applicable
|
|
|
|
|
Item 8.
|
|
Identification and Classification of Members of the Group
|
|
|
|
Not applicable
|
|
|
|
|
Item 9.
|
|
Notice of Dissolution of Group
|
|
|
|
Not applicable
|
|
|
|
|
|
|
|
CUSIP No. 019770 10 6
|
|
13G
|
|
Page
9
of 10 Pages
|
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of
business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any
transaction having that purpose or effect.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true,
complete and correct.
Dated: February 12, 2020
|
|
|
|
|
/s/ Arie Belldegrun
|
|
Arie Belldegrun, M.D.
|
|
|
|
Belldegrun Family Trust
|
|
|
|
|
By:
|
|
/s/ Arie Belldegrun
|
|
Name:
|
|
Arie Belldegrun, Trustee
|
|
|
|
Bellco Capital LLC
|
|
|
|
|
By:
|
|
/s/ Arie Belldegrun
|
|
Name:
|
|
Arie Belldegrun, Manager
|
|
|
|
VVAG Special Fund LLC
|
|
By: VVAG LLC, its Manager
|
|
|
|
|
By:
|
|
/s/ Arie Belldegrun
|
|
Name:
|
|
Arie Belldegrun, Senior Managing Director
|
|
|
|
Vida Ventures LLC
|
|
By: VV Manager LLC, its Manger
|
|
|
|
|
By:
|
|
/s/ Arie Belldegrun
|
|
Name:
|
|
Arie Belldegrun, Senior Managing Director
|
Allogene Therapeutics (NASDAQ:ALLO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Allogene Therapeutics (NASDAQ:ALLO)
Historical Stock Chart
From Apr 2023 to Apr 2024
